rasagiline has been researched along with Idiopathic Parkinson Disease in 259 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.77) | 18.7374 |
| 1990's | 2 (0.77) | 18.2507 |
| 2000's | 75 (28.96) | 29.6817 |
| 2010's | 150 (57.92) | 24.3611 |
| 2020's | 30 (11.58) | 2.80 |
| Authors | Studies |
|---|---|
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Balogh, B; Chai, CL; Chua, YY; Deme, R; Gölöncsér, F; Ho, HK; Huleatt, PB; Khoo, ML; Liew, RS; Magyar, K; Mátyus, P; Sheela, DP; Sperlágh, B; Tan, TW | 1 |
| Cai, P; Kong, L; Liu, Q; Wang, KDG; Wang, X; Wang, Z; Wu, J; Yang, X | 1 |
| Bao, XQ; Gao, F; Li, L; Tao, D; Wang, L; Wang, Y; Yang, BB; Zhang, D | 1 |
| Affini, A; Hagenow, S; Lutsenko, K; Reiner, D; Stark, H | 1 |
| Danış, Ö; Elzien Alamin Ali, H; Odabaş, Z; Ozalp, L | 1 |
| Archer, DB; Arpin, DJ; Burciu, RG; Chu, WT; Gao, H; Guttuso, T; Hess, CW; Lai, S; Malaty, IA; McFarland, NR; Mitchell, T; Okun, MS; Pasternak, O; Price, CC; Shukla, AW; Vaillancourt, DE; Wu, SS | 1 |
| Arai, M; Furusawa, Y; Hanya, Y; Hattori, N; Kitagawa, T; Mochizuki, H; Nagai, M; Takahashi, R; Takeda, A | 1 |
| Andrews, EB; Calingaert, B; Gordon, MF; Johannes, CB; Kaplan, S; Kaye, JA; Saltus, CW | 1 |
| Brotchie, J; Friedman, H; Giladi, N; Hauser, RA; Litman, P; Oren, S; Poewe, W | 1 |
| Beretta, J; Enzo, P; Mutti, C; Negrotti, A; Parrino, L; Pizzarotti, S; Rausa, F; Sarnataro, RB | 1 |
| Chang, HY; Hong, CT; Kuan, YC; Li, YY | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C | 1 |
| Iguchi, Y; Kitagawa, T; Komatsu, T; Maku, T; Mimori, M; Mitsumura, H; Murakami, H; Okumura, M; Omoto, S; Ozawa, M; Sakai, K; Sato, T; Shiraishi, T; Takatsu, H; Umehara, T | 1 |
| Bovenzi, R; Candelise, N; Ferri, A; Grillo, P; Mercuri, NB; Schirinzi, T; Simonetta, C; Valle, C; Zenuni, H | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Cao, S; Chen, H; Hu, X; Liang, Z; Liu, Z; Mao, W; Shao, M; Song, Z; Su, W; Tang, B; Wei, W; Wu, Y; Zhang, K | 1 |
| Gao, F; Gao, L; Miao, J; Yang, Y | 1 |
| Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI | 1 |
| Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Wang, HK; Wang, Y | 1 |
| Chung, YA; Heo, Y; Im, JJ; Jeong, H; Oh, JK; Park, JS; Song, IU | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
| Lv, C; Wang, M; Zhang, Q; Zhou, W; Zong, S | 1 |
| Maruyama, W; Naoi, M; Shamoto-Nagai, M | 1 |
| Alves, C; Gomes, P; Lázaro, DF; Outeiro, TF; Sharma, V; Silva, S; Vale, N | 1 |
| Parambi, DGT | 1 |
| Chappell, KB; Cutshall, BT; Sands, CW; Shah, SP | 1 |
| Hattori, N; Nagai, M | 1 |
| Del Rosario, MM; Jamora, RDG; Suratos, CTR | 1 |
| Binde, CD; Gåsemyr, JI; Klemp, M; Natvig, B; Tvete, IF | 1 |
| Fukuda, K; Hirano, M; Isono, C; Kusunoki, S; Samukawa, M | 1 |
| Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M | 1 |
| Matos, MJ | 1 |
| Alborghetti, M; Bianchini, E; De Carolis, L; Della Gatta, F; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Elmer, L; Friedman, H; Giladi, N; Hauser, RA; Kadosh, S; Kieburtz, K; Klepiskaya, OS; Kreitzman, DL; Leinonen, M; Lew, MF; Linvah, N; Litman, P; Olanow, CW; Russell, DS; The P B Study Group, F | 1 |
| Capece, R; Hauser, RA; Hewitt, DJ; Ho, TW; Huyck, S; Lines, C; Michelson, D; Rascol, O; Sklar, P; Stocchi, F; Tzontcheva, A | 1 |
| Canesi, M; Cereda, E; Cilia, R; Mariani, CB; Pezzoli, G; Tesei, S; Zecchinelli, AL | 1 |
| Lang, AE; Levy, A | 1 |
| Assogna, F; Pontieri, FE; Rinaldi, D; Sforza, M; Tagliente, S | 1 |
| Cronin, A; Grealy, M | 1 |
| Duan, D; Hua, H; Jiang, Y; Li, Y; Liu, W; Lu, X; Meng, Q; Mu, H; Sun, K; Wang, A; Wang, Y; Yan, X; Zhang, X | 1 |
| Brandt, MD; Brown, S; Fauser, M; Graehlert, X; Löhle, M; Maaß, A; Ossig, C; Otto, K; Reichmann, H; Schrempf, W; Schwanebeck, U; Storch, A; Wienecke, M | 1 |
| Magyar, K; Riederer, P; Szökő, É; Tábi, T; Vécsei, L | 1 |
| Müller, T; Riederer, P | 1 |
| Hattori, N; Kato, M; Mochizuki, H; Nagai, M; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S | 1 |
| Ahn, EH; Cao, X; Dhakal, S; Iuvone, PM; Kang, SS; Liu, X; Manfredsson, FP; Sandoval, IM; Ye, K; Zhang, Z | 1 |
| Liguori, C; Mercuri, NB; Pierantozzi, M; Ruffini, R; Stefani, A | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Hattori, N; Kitagawa, T; Mochizuki, H; Nagai, M; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S | 2 |
| Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM | 1 |
| Hattori, N; Mochizuki, H; Nagai, M; Nakaya, R; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S | 1 |
| Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A | 1 |
| Asano, AGC; Asano, NMJ; de Souza, PRE; Dos Santos, EUD; Duarte, EBC; Maia, MMD; Miranda, LMR | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Duval, F; Flabeau, O; Razafimahefa, J; Spampinato, U; Tison, F | 1 |
| Chen, Y; Deng, L; Li, J; Qin, X; Sun, H; Tang, R; Yi, L; Zhang, C; Zhang, L; Zhang, Z; Zheng, J; Zhou, H | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Berkovich, E; Brundin, P; Fitzer-Attas, C; Fog, K; Hickery, M; Kallunki, P; Petit, GH | 1 |
| de Groot, PW; Jordán, J; Mínguez-Mínguez, S; Solís-García del Pozo, J | 1 |
| Antonini, A; Baroni, L; Belgrado, E; Borsato, C; Capozzoli, F; Gioulis, M; Marchini, C; Vitaliani, R; Volpe, D; Zambito Marsala, S | 1 |
| Jordán, J; Mínguez-Mínguez, S; Solís-García Del Pozo, J | 1 |
| Inaba-Hasegawa, K; Maruyama, W; Naoi, M | 1 |
| Lew, MF | 1 |
| Stocchi, F | 2 |
| Ansorena, E; Blanco-Prieto, MJ; Garbayo, E | 1 |
| Elmer, LW | 1 |
| Jost, WH | 1 |
| Hernández-Vara, J; Salvado, M | 1 |
| Galvez-Jimenez, N; Kurako, K; Reyes, D | 1 |
| Fauser, M; Haehner, A; Hummel, T; Klingelhöfer, L; Reichmann, H; Storch, A; Wolz, M | 1 |
| Bartl, J; Gerlach, M; Grünblatt, E; Müller, T; Riederer, P | 1 |
| Camacho-Ordoñez, A; Cervantes-Arriaga, A; González-Latapi, P; Martínez-Ramírez, D; Rodríguez-Violante, M; Velázquez-Osuna, S | 1 |
| Kulisevsky, J; Pagonabarraga, J | 2 |
| Mendzelevski, B; Rabinovich-Guilatt, L; Spiegelstein, O; Sprenger, CR | 1 |
| Berkovich, E; Eyal, E; Jankovic, J; Tolosa, E | 1 |
| Cesaro, P; Defebvre, L | 1 |
| Cosentino, G; D'Amelio, M; Fierro, B; Mastrilli, S; Realmuto, S; Savettieri, G; Valentino, F | 1 |
| Ali, A; Ali, J; Baboota, S; Fazil, M; Hasan, Q; Md, S; Mittal, D | 1 |
| Kozak, HH; Uca, AU | 1 |
| Bernardi, G; Brusa, L; Finazzi Agro', E; Iani, C; Musco, S; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Miklya, I | 1 |
| Choudhry, A; Eyal, E; Hauser, RA; Isaacson, S; Silver, D | 1 |
| Marconi, S; Zwingers, T | 1 |
| Bertotti, G; Boveri, N; Comi, C; Frazzitta, G; Ghilardi, MF; Maestri, R; Perini, M; Pezzoli, G; Riboldazzi, G; Turla, M; Uccellini, D | 1 |
| Müller, T | 1 |
| Chen, JJ; Conner, J; Mathena, J; Panisset, M; Rhyee, SH | 1 |
| McCormack, PL | 1 |
| Cai, B; Cai, JP; Chen, WJ; Lin, Y; Wang, N | 1 |
| Eyal, E; Smith, KM; Weintraub, D | 1 |
| Hauser, RA; Lang, A; Poewe, W | 1 |
| Hanagasi, HA | 1 |
| Abbruzzese, G; Antonini, A; Barone, P; Bonuccelli, U; Cossu, G; Lopiano, L; Meco, G; Morgante, L; Onofrj, M; Pezzoli, G; Santangelo, G; Stanzione, P; Tinazzi, M | 1 |
| Habersack, A; Haehner, A; Hummel, T; Reichmann, H; Storch, A; Wienecke, M | 1 |
| Fossati, C; Stocchi, F; Torti, M | 1 |
| Gaillon, G; Le Goff, F; Lefaucheur, R; Maltête, D; Triquenot-Bagan, A | 1 |
| Buda, S; Degli Esposti, L; Nobili, F; Piccinni, C; Sangiorgi, D | 1 |
| Boger, HA; Cantwell, K; Granholm, AC; Hinson, VK; Ledreux, A | 1 |
| Fernandez, HH; Gujrati, Y; Hennessy, C; Kluger, BM; Lim, TT; Malaty, IA; Nutter, B; Ojo, OO; Palacio, R; Patel, S; Rodriguez, RL; Swartz, C | 1 |
| Abler, V; Eliaz, RE; Eyal, E; Hauser, RA | 1 |
| Santimaleeworagun, W; Supasyndh, O; Suphanklang, J | 1 |
| Choudhry, A; Davis, MD; Elm, JJ; Hauser, RA; Pagan, F; Weintraub, D | 1 |
| Burciu, RG; Chung, JW; McFarland, NR; Ofori, E; Okun, MS; Pasternak, O; Shukla, P; Vaillancourt, DE | 1 |
| Benetin, J; Cibulcik, F; Donath, V; Dvorak, M; Grofik, M; Kothaj, J; Kurca, E; Minar, M; Richter, D; Valkovic, P | 1 |
| Abler, V; Berkovich, E; Collinson, S; Eliaz, RE; Eyal, E; Fitzer-Attas, C; Freeman, N; Grossman, I; Hayden, MR; Kennedy, JL; Knight, J; Lang, AE; Levy, J; Masellis, M; Tampakeras, M; Tchelet, A; Tiwari, A | 1 |
| Csóka, M; Domján, G; Kellős, É; Molnár, S | 1 |
| Fyfe, I | 1 |
| Katunina, EA; Sotnikova, NN; Titova, NV | 1 |
| Cerdán, DM; Duarte, J; Fernández, B; Simonet, C | 1 |
| Abler, V; Fitzer-Attas, CJ; Hauser, RA; Olanow, CW; Rascol, O; Sidi, Y; Stocchi, F | 1 |
| Jog, M; Rahimi, F; Roberts, AC | 1 |
| Bélanger, M; Chouinard, S; Coffin, D; Lehoux, G; Panisset, M; Stril, JL | 1 |
| Frakey, LL; Friedman, JH | 1 |
| Desbordes, M; Gaillon, G; Guillaume, M; Hébant, B; Lefaucheur, R; Maltête, D | 1 |
| Alawadi, F; Bashier, A; Hussain, AA; Ibrahim, FA; Rashid, F | 1 |
| Chang, Y; Lei, K; Li, D; Liu, SY; Wang, LB | 1 |
| Grünblatt, E; Müller, T; Riederer, P | 1 |
| Salzman, P; Schwid, SR; White, WB | 1 |
| Jost, WH; Klasser, M; Reichmann, H | 1 |
| Eyal, E; Hauser, RA; Jankovic, J; Lang, A; Langston, W; Melamed, E; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Bertoni, JM; Elmer, LW | 1 |
| Bats, JW; Brüning, J; Schmidt, MU | 1 |
| Levin, OS | 1 |
| Isaacson, SH | 1 |
| Fitzer-Attas, CJ; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J | 1 |
| Olanow, CW; Schapira, AH | 1 |
| Azulay, T; Brooks, DJ; Giladi, N; Melamed, E; Oertel, W; Poewe, WH; Rascol, O; Stocchi, F; Tal, J; Tolosa, E | 1 |
| Brotchie, J; Fitzer-Attas, C | 1 |
| Klivényi, P; Rákóczi, K; Vécsei, L | 1 |
| Lewitt, PA | 2 |
| Amit, T; Drigues, N; Sagi, Y; Weinreb, O; Youdim, MB | 1 |
| Armand, C; Cochran, J; François, C; Haycox, A; Murteira, S | 1 |
| Chuang, RS; Lang, AE | 1 |
| Feigin, PD; Hauser, R; Jankovic, J; Lang, A; Langston, W; Melamed, E; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Burke, WJ; Lewitt, PA | 1 |
| Amit, T; Bar-Am, O; Weinreb, O; Youdim, MB | 2 |
| Reichmann, H | 2 |
| Youdim, MB | 2 |
| Schwarzschild, MA | 2 |
| Büttner, T; Csoti, I; Kassubek, J; Reichmann, H; Riederer, P; Schulz, JB; Wüllner, U | 1 |
| Ferreira, JJ; Sampaio, C | 1 |
| Jost, WH; Reichmann, H | 1 |
| Chen, JJ | 1 |
| Olanow, CW; Rascol, O | 1 |
| Ahlskog, JE; Uitti, RJ | 2 |
| Adar, L; Goren, T; Sasson, N; Weiss, YM | 1 |
| Fitzer-Attas, CJ; Goren, T; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J | 1 |
| Bortan, E; Leegwater-Kim, J | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Andronis, CA; Deftereos, SN | 1 |
| Vanacore, N | 1 |
| Korczyn, AD; Vakhapova, V | 1 |
| Williams, R | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Bloem, BR; Boon, AJ; van Laar, T | 1 |
| Montgomery, EB | 1 |
| Knudsen Gerber, DS | 1 |
| Janszky, J; Kovacs, N; Nagy, F | 1 |
| Barker, RA; Evans, JR | 1 |
| Keller, D | 1 |
| Fernandes, C; Kessel, B; Reddy, P | 1 |
| Boĭko, AN; Ivanov, AK; Levin, OS | 1 |
| Auinger, P; Hauser, RA | 1 |
| Perez-Lloret, S; Rascol, O | 1 |
| Eyal, E; Fitzer-Attas, CJ; Hauser, R; Jankovic, J; Lang, A; Langston, JW; Melamed, E; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E; Weiss, YM | 1 |
| Cakmur, R; Emre, M; Feyzioglu, A; Gunal, DI; Gurvit, H; Hanagasi, HA; Horozoglu, H; Sahin, HA; Tuncer, N; Unsalan, P; Yener, GG | 1 |
| Chen, JJ; Wilkinson, JR | 1 |
| Buck, PO; Silver, DE | 1 |
| Stern, MB; Tolosa, E | 1 |
| Rabey, JM; Stocchi, F | 1 |
| Rascol, O | 3 |
| Bel'gusheva, ME; Fedorova, NV; Tekaeva, FK | 1 |
| Jenner, P; Langston, JW | 1 |
| Amit, T; Mandel, SA; Riederer, P; Weinreb, O; Youdim, MB | 1 |
| Chahine, LM; Stern, MB | 1 |
| Conner, JB; Griffith, A; Salzman, PM; Seeberger, LC; Silver, D; Wilson, RE | 1 |
| Amboni, M; Barone, P; Bombieri, F; Di Matteo, A; Fasano, A; Ferigo, L; Santangelo, G; Squintani, G; Tinazzi, M; Vitale, C | 1 |
| Christine, CW; Marks, WJ; Ostrem, JL | 1 |
| Tarrants, ML; Zagmutt, FJ | 1 |
| Hoy, SM; Keating, GM | 1 |
| Alvarez, MV; Grogan, PM | 1 |
| Lee, AD; Strowd, LC; Yosipovitch, G | 1 |
| Belavic, J | 1 |
| Hoy, SM; Keating, GM; Lyseng-Williamson, KA | 1 |
| Barcia, E; Fernández, M; Fernández-Carballido, A; Garcia, L; Negro, S; Slowing, K | 1 |
| García-Ruiz, PJ; Luquin, MR | 1 |
| Blin, O; Lancrenon, S; Pitel, S; Viallet, F | 1 |
| Olanow, CW | 2 |
| Dimpfel, W; Hoffmann, JA; Müller, T; Oehlwein, C | 1 |
| Pagonabarraga, J; Rodríguez-Oroz, MC | 1 |
| Barone, P; Errico, D; Erro, R; Improta, I; Manganelli, F; Moccia, M; Santangelo, G; Vitale, C | 1 |
| Blindauer, K; Kieburtz, K; McDermott, M; Plumb, S; Shoulson, I; Siderowf, A | 1 |
| Amit, T; Bar-Am, O; Weinstock, M; Yogev-Falach, M; Youdim, MB | 1 |
| Lazarovici, P; Lecht, S; Tabakman, R | 1 |
| Friedman, J; Hauser, RA; LeWitt, PA; Marek, KL; Olanow, CW; Stern, MB; Tarsy, D | 1 |
| Jenner, P | 1 |
| Fridkin, M; Youdim, MB; Zheng, H | 1 |
| Ludin, HP | 1 |
| Goetz, CG | 1 |
| Plosker, GL; Siddiqui, MA | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Jankovic, J; Olanow, CW | 1 |
| Amit, T; Mandel, S; Weinreb, O; Youdim, MB | 1 |
| Konitsiotis, S | 1 |
| Blandini, F | 1 |
| Chen, JJ; Swope, DM | 1 |
| Oberpichler-Schwenk, H | 1 |
| Shults, CW | 1 |
| Bate, G; Kirkpatrick, P; Schapira, A | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Miletzki, A | 1 |
| Schapira, AH | 2 |
| Burgut, FT; Henchcliffe, C; Schumacher, HC | 1 |
| Bakhle, YS; Youdim, MB | 1 |
| Biglan, KM; Blindauer, K; Eberly, S; Fahn, S; Goren, T; Kieburtz, K; Oakes, D; Plumb, S; Schwid, S; Shoulson, I; Siderowf, A; Stern, M | 1 |
| Sharma, JC | 1 |
| Cochran, JM; Eckert, L; Hudry, J; Keränen, T; Rinne, JO | 1 |
| Chen, JJ; Ly, AV | 1 |
| Eberly, SW; Goetz, CG; Oakes, D; Schwid, SR; Shoulson, I | 1 |
| Siderowf, A; Stern, M | 1 |
| Blindauer, K; Eberly, S; Elmer, L; Fahn, S; Goetz, C; Kieburtz, K; Oakes, D; Oren, S; Prisco, UL; Salzman, P; Schwid, S; Shoulson, I; Stern, M | 1 |
| Blindauer, K; deMarcaida, JA; Fahn, S; Kieburtz, K; Schwid, SR; Shoulson, I; Stern, M; White, WB | 1 |
| Uitti, RJ; Wszolek, ZK | 1 |
| Guay, DR | 1 |
| Keating, GM; Oldfield, V; Perry, CM | 1 |
| Chen, JJ; Fernandez, HH | 2 |
| Hermanowicz, N | 1 |
| Akao, Y; Maruyama, W; Naoi, M; Shamoto-Nagai, M; Yamaoka, Y; Yi, H | 1 |
| Chen, JJ; Dashtipour, K; Swope, DM | 1 |
| Freeman, JW; Matos, E; Simmons, M | 1 |
| Linazasoro, G | 1 |
| Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J | 1 |
| Maruyama, W; Naoi, M | 1 |
| Bradford, HF; Goggi, J; Jauniaux, E; Riaz, SS; Stern, GM; Theofilopoulos, S | 1 |
| Akao, Y; Davis, BA; Maruyama, W; Naoi, M; Youdim, MB | 1 |
| Kupsch, A | 1 |
| Riederer, P; Youdim, MB | 1 |
| Finberg, JP; Youdim, MB | 1 |
83 review(s) available for rasagiline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
Topics: Humans; Indans; Levodopa; Parkinson Disease; Pramipexole | 2022 |
Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Databases, Factual; Humans; Indans; Parkinson Disease; Randomized Controlled Trials as Topic | 2022 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic | 2020 |
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apoptosis; Homeostasis; Humans; Indans; Mitochondria; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
[Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Indans; Japan; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2020 |
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2020 |
Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?
Topics: Alzheimer Disease; Donepezil; Drug Synergism; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Protein Aggregates; Small Molecule Libraries | 2021 |
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotection; Neuroprotective Agents; Parkinson Disease; Selegiline | 2018 |
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Selegiline | 2018 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2013 |
Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Topics: Antiparkinson Agents; Humans; Indans; Parkinson Disease | 2013 |
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
Topics: Animals; Apoptosis; Gene Expression; Genes, bcl-2; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Selegiline | 2013 |
Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
Topics: Animals; Blood-Brain Barrier; Dopamine; Drug Delivery Systems; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2013 |
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome | 2014 |
[Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].
Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2014 |
Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2014 |
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Disease Progression; Humans; Indans; Monoamine Oxidase Inhibitors; Nitriles; Oxidative Stress; Parkinson Disease; Selegiline | 2014 |
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2014 |
Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2015 |
Rasagiline for the treatment of Parkinson's disease: an update.
Topics: Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Cognition Disorders; Drug Therapy, Combination; Fatigue; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Quality of Life | 2015 |
Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
Topics: Clinical Trials, Phase III as Topic; Humans; Indans; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2016 |
[Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
Topics: Aged; Antiparkinson Agents; Comorbidity; Depression; Fatigue; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2016 |
Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
Topics: Animals; Clinical Trials as Topic; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2008 |
[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2008 |
Mechanisms compensating for dopamine loss in early Parkinson disease.
Topics: Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine; Globus Pallidus; Humans; Indans; Levodopa; Neural Pathways; Neurons; Parkinson Disease | 2009 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone | 2009 |
MAO-B inhibitor know-how: back to the pharm.
Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2009 |
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
Topics: Animals; Cytochrome P-450 Enzyme System; Humans; Indans; Models, Chemical; Neuroprotective Agents; Parkinson Disease; Proto-Oncogene Proteins c-bcl-6 | 2010 |
[Diagnosis and therapy of idiopathic Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Deep Brain Stimulation; Diagnosis, Differential; Dopamine Agonists; Humans; Indans; Levodopa; Mental Status Schedule; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2006 |
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methylaspartate; Parkinson Disease; Piperidines; Selegiline | 2010 |
Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Early Diagnosis; Health Care Costs; Humans; Indans; Middle Aged; Parkinson Disease; Quality of Life | 2010 |
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Topics: Activities of Daily Living; Disability Evaluation; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Observer Variation; Outcome Assessment, Health Care; Parkinson Disease; Patient Satisfaction; Patient Selection; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Severity of Illness Index; Time Factors | 2010 |
The role of rasagiline in the treatment of Parkinson's disease.
Topics: Aged; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Disease Models, Animal; Humans; Indans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Protein Structure, Quaternary; Selegiline | 2010 |
[Rasagiline: effectiveness and protection in Parkinson's disease].
Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2010 |
Selegiline and rasagiline: twins or distant cousins?
Topics: Humans; Inactivation, Metabolic; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2011 |
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
Topics: Disease Progression; Endpoint Determination; Humans; Indans; Movement Disorders; Neuroprotective Agents; Parkinson Disease; Posture; Reflex, Abnormal; Research Design; Treatment Outcome | 2011 |
Safety of rasagiline for the treatment of Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Food-Drug Interactions; Humans; Indans; Parkinson Disease; Serotonin Agents; Treatment Outcome | 2011 |
The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Topics: Antiparkinson Agents; Brain; Dietary Proteins; Dose-Response Relationship, Drug; Food-Drug Interactions; Humans; Hypertension; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Safety; Risk Assessment; Risk Factors; Treatment Outcome; Tyramine | 2012 |
Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
Topics: Databases, Factual; Humans; Hypokinesia; Indans; Neuroprotective Agents; Parkinson Disease | 2011 |
Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
Topics: Animals; Cell Death; Clinical Trials as Topic; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease | 2011 |
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Topics: Animals; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship | 2011 |
Rasagiline in Parkinson's disease.
Topics: Animals; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2011 |
Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
Topics: Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Cross-Sectional Studies; Databases, Bibliographic; Fatigue; Female; Gastrointestinal Diseases; Humans; Indans; Indoles; Logistic Models; Male; Parkinson Disease; Patient Dropouts; Pramipexole; Sleep Wake Disorders; Treatment Outcome | 2012 |
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2012 |
[Limits of conventional oral and transdermal medication in Parkinson's disease].
Topics: Administration, Cutaneous; Administration, Oral; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Indans; Injections, Subcutaneous; Levodopa; Meta-Analysis as Topic; Multicenter Studies as Topic; Parkinson Disease | 2012 |
[Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Topics: Antiparkinson Agents; Attention; Clinical Trials as Topic; Cognition Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Fatigue; Headache; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Multicenter Studies as Topic; Nausea; Neuroprotective Agents; Parkinson Disease; Severity of Illness Index | 2013 |
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Haplorhini; Humans; Inactivation, Metabolic; Indans; Mice; Mice, Transgenic; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Oxepins; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Selegiline | 2004 |
Clinical trials of neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Humans; Indans; Minocycline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuroprotective Agents; Oxepins; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Riluzole; Selegiline; Ubiquinone | 2004 |
[Are there innovations in the treatment of Parkinson's disease?].
Topics: Antiparkinson Agents; Cannabis; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dopamine Agonists; Heart Valve Diseases; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pergolide; Phenylcarbamates; Placebos; Rivastigmine; Time Factors | 2004 |
Movement disorders: understanding clinical trials.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Indans; Movement Disorders; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design; Tomography, Emission-Computed, Single-Photon | 2005 |
Rasagiline.
Topics: Biological Availability; Clinical Trials as Topic; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2005 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E | 2005 |
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Topics: Amyloid beta-Peptides; Animals; Apoptosis; Brain Chemistry; Ferritins; Humans; Indans; Mitochondria; Models, Neurological; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Protein Kinase C; Signal Transduction | 2005 |
Novel pharmacological strategies for motor complications in Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Indans; Levodopa; Liposomes; Monoamine Oxidase Inhibitors; Motor Neurons; Movement Disorders; Nitriles; Parkinson Disease; Receptors, Glutamate; Signal Transduction | 2005 |
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
Topics: Animals; Apoptosis; Humans; Indans; Models, Neurological; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2005 |
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Topics: Animals; Clinical Trials as Topic; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline | 2005 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
Rasagiline in the pharmacotherapy of Parkinson's disease--a review.
Topics: Antiparkinson Agents; Humans; Indans; Parkinson Disease | 2005 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence | 2005 |
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Diet Therapy; Dopamine Agents; Drug Evaluation; Drug Interactions; Expert Testimony; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2005 |
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Topics: Animals; Cholinesterase Inhibitors; Dementia; Depressive Disorder; History, 20th Century; History, 21st Century; Humans; Indans; Iron; Iron Deficiencies; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline | 2006 |
Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
Topics: Delayed-Action Preparations; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2006 |
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Topics: Clinical Trials as Topic; Drug Interactions; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2006 |
Concerning neuroprotective therapy for Parkinson's disease.
Topics: Clinical Trials as Topic; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2006 |
Rasagiline (Azilect) for Parkinson's disease.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2006 |
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Humans; Hydroxyquinolines; Indans; Models, Biological; Neuroprotective Agents; Parkinson Disease; Selegiline | 2006 |
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2006 |
The use of rasagiline in Parkinson's disease.
Topics: Animals; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2006 |
Rasagiline: a review of its use in the management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2007 |
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Topics: Aged; Aging; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Homes for the Aged; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Selegiline | 2007 |
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline | 2007 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
Parkinson disease: an incremental challenge.
Topics: Catechols; Deep Brain Stimulation; Disease Progression; Humans; Indans; Nitriles; Parkinson Disease | 2007 |
[Rasagiline in Parkinson's disease].
Topics: Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2008 |
54 trial(s) available for rasagiline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
Topics: Diffusion Magnetic Resonance Imaging; Disease Progression; Double-Blind Method; Humans; Indans; Parkinson Disease; Prospective Studies | 2022 |
Effects of rasagiline on Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson's disease: A post-hoc analysis of clinical trials in Japan.
Topics: Aged; Antiparkinson Agents; Emotions; Female; Humans; Indans; Japan; Male; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2022 |
Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Asian People; Body Mass Index; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Safety; Transdermal Patch | 2020 |
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Indans; Israel; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Severity of Illness Index; Triethylenemelamine; United States | 2017 |
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
Topics: Activities of Daily Living; Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Internationality; Male; Middle Aged; Motor Activity; Parkinson Disease; Pyrimidines; Severity of Illness Index; Treatment Failure; Triazoles | 2017 |
Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Polysomnography; Sleep; Sleep Wake Disorders; Treatment Outcome | 2018 |
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adult; Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2018 |
Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
Topics: Adult; Aged; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indans; Japan; Male; Middle Aged; Monoamine Oxidase Inhibitors; Nasopharyngitis; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index | 2019 |
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Treatment Outcome | 2019 |
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Female; Humans; Indans; Japan; Male; Middle Aged; Parkinson Disease; Time | 2019 |
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Topics: Adult; Aged; Antiparkinson Agents; Asian People; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2013 |
Rasagiline treatment effects on parkinsonian tremor.
Topics: Databases, Factual; Double-Blind Method; Female; Humans; Indans; Male; Neuroprotective Agents; Parkinson Disease; Treatment Outcome; Tremor | 2013 |
Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Fatigue; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2013 |
Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
Topics: Administration, Intranasal; Aged; Double-Blind Method; Electroencephalography; Evoked Potentials; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Olfaction Disorders; Olfactometry; Parkinson Disease; Prospective Studies; Psychophysics; Quality of Life; Severity of Illness Index | 2013 |
Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Young Adult | 2014 |
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
Topics: Cohort Studies; Double-Blind Method; Female; Humans; Indans; Male; Motor Activity; Neuroprotective Agents; Parkinson Disease | 2014 |
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Urinary Bladder; Urodynamics | 2014 |
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Topics: Aged; Dopamine Agonists; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Time Factors; United States | 2014 |
Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disease Progression; Exercise Therapy; Female; Follow-Up Studies; Humans; Indans; Male; Parkinson Disease; Pilot Projects; Severity of Illness Index; Treatment Outcome; Walking | 2015 |
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Apathy; Depression; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep; Treatment Outcome; Wakefulness | 2015 |
Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
Topics: Activities of Daily Living; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Topics: Cognition Disorders; Double-Blind Method; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2015 |
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
Topics: Aged; Depression; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2015 |
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Medical Futility; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pioglitazone; Selegiline; Thiazolidinediones; Treatment Outcome | 2015 |
Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Fatigue; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2015 |
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
Topics: Aged; Cognitive Dysfunction; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2016 |
Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Drug Administration Schedule; Female; Gait Disorders, Neurologic; Humans; Indans; Male; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2016 |
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
Topics: Aged; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Dopamine D2; Severity of Illness Index; Tandem Repeat Sequences | 2016 |
Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cognition; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Topics: Aged; Antihypertensive Agents; Antiparkinson Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Food; Humans; Hypertension; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Postprandial Period; Supine Position; Telephone; Tyramine | 2008 |
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2008 |
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indans; Levodopa; Longitudinal Studies; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Reproducibility of Results; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Catechols; Double-Blind Method; Female; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Nitriles; Parkinson Disease; Principal Component Analysis; Psychiatric Status Rating Scales; Reproducibility of Results; Severity of Illness Index; Statistics as Topic; Surveys and Questionnaires | 2009 |
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Research Design; Severity of Illness Index | 2009 |
Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease.
Topics: Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2010 |
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Topics: Adult; Aged; Algorithms; Contraindications; Diet; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Humans; Hypertension; Indans; Isoenzymes; Male; Methoxyhydroxyphenylglycol; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tyramine; United States | 2010 |
Long-term efficacy of rasagiline in early Parkinson's disease.
Topics: Antiparkinson Agents; Cohort Studies; Disease Progression; Dopamine Agents; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Indans; Kaplan-Meier Estimate; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Determination of minimal clinically important change in early and advanced Parkinson's disease.
Topics: Antiparkinson Agents; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Placebo Effect; ROC Curve; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Attention; Cognition Disorders; Dementia; Double-Blind Method; Executive Function; Female; Humans; Indans; Language; Male; Memory; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Visual Perception | 2011 |
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2012 |
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dysarthria; Facial Expression; Female; Humans; Hypokinesia; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Muscle Rigidity; Nitriles; Parkinson Disease; Severity of Illness Index; Tremor | 2011 |
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Hypokinesia; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies; Time Factors | 2011 |
Hyposmia in Parkinson's disease.
Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Olfaction Disorders; Parkinson Disease | 2012 |
Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Sleep Wake Disorders; Time Factors | 2013 |
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Female; Humans; Indans; Male; Mental Status Schedule; Middle Aged; Motor Skills; Neurologic Examination; Observer Variation; Parkinson Disease; Reproducibility of Results | 2002 |
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
Topics: Aged; Chi-Square Distribution; Double-Blind Method; Female; Humans; Indans; Logistic Models; Male; Middle Aged; Parkinson Disease | 2002 |
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cohort Studies; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 2004 |
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2004 |
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Topics: Aged; Aged, 80 and over; Anorexia; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Vomiting; Weight Loss | 2005 |
Rasagiline improves quality of life in patients with early Parkinson's disease.
Topics: Aged; Analysis of Variance; Chi-Square Distribution; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2006 |
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
Topics: Aged; Behavioral Symptoms; Case-Control Studies; Cognition; Dopamine Agents; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease | 2006 |
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Food-Drug Interactions; Heart Rate; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Risk Factors; Tyramine | 2006 |
122 other study(ies) available for rasagiline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Pargyline; Parkinson Disease; PC12 Cells; Propylamines; Rats; Structure-Activity Relationship | 2015 |
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Rats; Small Molecule Libraries; Structure-Activity Relationship | 2016 |
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
Topics: Animals; Coumarins; Dose-Response Relationship, Drug; Drug Discovery; Humans; Inflammation; Male; Mannich Bases; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Rasagiline derivatives combined with histamine H
Topics: Histamine H3 Antagonists; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Histamine H3 | 2019 |
Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
Topics: Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2022 |
The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Female; Humans; Indans; Male; Medicare; Melanoma; Parkinson Disease; Retrospective Studies; Skin Neoplasms; United States | 2022 |
Rasagiline, sleep quality and well-being in Parkinson's disease: a pilot study.
Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Quality of Life; Sleep Quality | 2022 |
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Topics: Aged; Antiparkinson Agents; Belgium; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson's disease are dependent on frontal function.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2023 |
Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On.
Topics: Biomarkers; Humans; Lactates; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.
Topics: Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; East Asian People; Humans; Levodopa; Parkinson Disease; Prospective Studies; Treatment Outcome | 2023 |
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease | 2023 |
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
Topics: Amphetamines; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selegiline | 2023 |
Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2019 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |
A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model.
Topics: alpha-Synuclein; Blood-Brain Barrier; Cell Culture Techniques; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Carriers; Drug Design; Drug Evaluation, Preclinical; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological; Solid-Phase Synthesis Techniques | 2020 |
Ciprofloxacin-rasagiline drug interaction leading to dopaminergic effects.
Topics: Aged; Ciprofloxacin; Dopamine Agents; Drug Interactions; Humans; Indans; Male; Nurse Practitioners; Parkinson Disease | 2020 |
Serotonin syndrome in a Parkinson disease patient after intake of an ethanol-containing homeopathic medication.
Topics: Aged; Citalopram; Drug Interactions; Ethanol; Female; Homeopathy; Humans; Indans; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2020 |
Rasagiline monotherapy improves swallowing in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Deglutition Disorders; Female; Fluoroscopy; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2020 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2021 |
Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Substitution; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies | 2021 |
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Follow-Up Studies; Humans; Indans; Italy; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index | 2017 |
Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease.
Topics: Adult; Disruptive, Impulse Control, and Conduct Disorders; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Executive Function; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Treatment Outcome | 2018 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish | 2017 |
Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.
Topics: Animals; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gels; Indans; Injections; Male; Mesylates; Microspheres; Oxidopamine; Parkinson Disease; Phase Transition; Rats; Rats, Sprague-Dawley | 2018 |
α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cysteine Endopeptidases; Disease Models, Animal; Dopamine; Indans; Mice; Mice, Transgenic; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Sleep; Sleep Wake Disorders; Surveys and Questionnaires | 2018 |
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats | 2019 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
Topics: Antiparkinson Agents; Catechols; Cross-Sectional Studies; Dopamine; Dopamine Agonists; Genotype; Humans; Indans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D3; Selegiline | 2019 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.
Topics: Aged; Akathisia, Drug-Induced; Antiparkinson Agents; Brain Diseases; Delusions; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Humans; Indans; Myoclonus; Neuroprotective Agents; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Sertraline | 2013 |
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Topics: Age Factors; alpha-Synuclein; Animals; Disease Models, Animal; Humans; Indans; Memory, Short-Term; Mice; Mice, Transgenic; Monoamine Oxidase Inhibitors; Olfaction Disorders; Olfactory Bulb; Parkinson Disease; Smell | 2013 |
Rapid onset of efficacy of rasagiline in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Single-Blind Method; Treatment Outcome | 2013 |
Rasagiline in Parkinson's disease: the show must go on.
Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2013 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease | 2014 |
Rasagiline induced hypersexuality in Parkinson's disease.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Sexual Dysfunctions, Psychological | 2014 |
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2014 |
Apathy and associated factors in Mexican patients with Parkinson's disease.
Topics: Age of Onset; Antiparkinson Agents; Apathy; Body Mass Index; Cross-Sectional Studies; Dopamine Agonists; Female; Humans; Indans; Male; Mexico; Middle Aged; Parkinson Disease; Prevalence; Psychiatric Status Rating Scales; Severity of Illness Index | 2014 |
Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dystonia; Female; Humans; Indans; Parkinson Disease | 2014 |
Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.
Topics: Administration, Intranasal; Animals; Biological Availability; Brain; Chemistry, Pharmaceutical; Chitosan; Drug Compounding; Drug Delivery Systems; Goats; Indans; Male; Mice; Nanoparticles; Nasal Mucosa; Neuroprotective Agents; Parkinson Disease; Tissue Distribution | 2016 |
A case of rasagiline-induced spontaneous orgasms in a female patient.
Topics: Adult; Antiparkinson Agents; Female; Humans; Indans; Orgasm; Parkinson Disease; Sexual Dysfunctions, Psychological | 2014 |
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Topics: Animals; Indans; Learning Disabilities; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tetrabenazine | 2014 |
Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
Topics: Aged; Antidepressive Agents, Second-Generation; Cohort Studies; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; United States | 2014 |
Early Parkinson's disease patients on rasagiline present with better odor discrimination.
Topics: Antiparkinson Agents; Cross-Sectional Studies; Discrimination, Psychological; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Odorants; Olfaction Disorders; Olfactory Perception; Parkinson Disease; Physical Stimulation; Prospective Studies; Psychophysics; Sensory Thresholds; Severity of Illness Index; Treatment Outcome | 2015 |
Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
Topics: Anticoagulants; Antiparkinson Agents; Biotransformation; Dizziness; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Indans; Male; Middle Aged; Parkinson Disease; Rivaroxaban; Trihexyphenidyl; Venous Thrombosis; Warfarin | 2015 |
Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
Topics: Aged; Antiparkinson Agents; Female; Health Care Costs; Hospitalization; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 2016 |
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease.
Topics: Animals; Behavior, Animal; Benzylamines; Brain; Brain-Derived Neurotrophic Factor; Chaperonin 60; Cognition; Disease Models, Animal; Dopamine; Indans; Locomotion; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Norepinephrine; Parkinson Disease; Rats; Rats, Inbred F344 | 2016 |
Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature.
Topics: Aged; Citalopram; Depression; Humans; Indans; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Treatment Outcome; Withholding Treatment | 2015 |
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.
Topics: Aged; Brain Mapping; Cross-Sectional Studies; Female; Humans; Indans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Substantia Nigra; Water | 2016 |
[Problem solving care models for Parkinson's disease].
Topics: Accidental Falls; Activities of Daily Living; Aged, 80 and over; Antiparkinson Agents; Cognitive Dysfunction; Constipation; Deglutition Disorders; Eating; Female; Hallucinations; Holistic Nursing; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Patient Care Team; Pneumonia; Pressure Ulcer; Problem Solving; Psychomotor Agitation; Quality of Life; Skin Care; Sleep Initiation and Maintenance Disorders; Walking | 2016 |
Parkinson disease: Dopamine receptor variants improve response to rasagiline in PD.
Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Dopamine D2 | 2016 |
Hypersexuality induced by rasagiline in monotherapy in Parkinson's disease.
Topics: Aged; Humans; Indans; Male; Neuroprotective Agents; Parkinson Disease; Sexual Behavior | 2016 |
Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
Topics: Aged; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease | 2016 |
Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
Topics: Aged; Female; Gait Disorders, Neurologic; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Pilot Projects | 2016 |
Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Psychiatric Status Rating Scales; Retrospective Studies; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome | 2016 |
Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient.
Topics: Aged; Depressive Disorder, Major; Drug Interactions; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2016 |
Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report.
Topics: Adult; Female; Humans; Hypoglycemia; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors; Treatment Outcome | 2017 |
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome | 2008 |
Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)).
Topics: Crystallization; Crystallography, X-Ray; Hydrogen Bonding; Indans; Molecular Structure; Monoamine Oxidase Inhibitors; Parkinson Disease | 2008 |
Selective MAO-B inhibitors have low potential for the tyramine effect.
Topics: Blood Pressure; Heart Rate; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Tyramine | 2010 |
Drug selection and timing of initiation of treatment in early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Indans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Time Factors | 2008 |
Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.
Topics: Animals; Antiparkinson Agents; Biomarkers; Cell Survival; Female; Genomics; Indans; Nerve Growth Factors; Nerve Tissue Proteins; Neurogenesis; Neuroprotective Agents; Parkinson Disease; Proteomics; Rats; Rats, Wistar; Selegiline; Signal Transduction; Substantia Nigra | 2009 |
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Dopamine Agonists; Female; Health Care Costs; Humans; Indans; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Monoamine Oxidase Inhibitors; Monte Carlo Method; Parkinson Disease; Pramipexole; Probability; Quality-Adjusted Life Years; State Medicine; Treatment Outcome; United Kingdom | 2009 |
Rasagiline-induced spontaneous ejaculation.
Topics: Aged; Antiparkinson Agents; Ejaculation; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Sexual Behavior; Sexual Dysfunction, Physiological; Spinal Dysraphism | 2009 |
Mao-B inhibitor know-how: back to the pharm.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Substantia Nigra | 2009 |
Rasagiline in Parkinson's disease.
Topics: Animals; Dose-Response Relationship, Drug; Humans; Indans; Mice; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptor Protein-Tyrosine Kinases | 2010 |
Rasagiline in Parkinson's disease.
Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Research Design | 2010 |
Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.
Topics: Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Time Factors | 2010 |
The delayed-start study in Parkinson disease: can't satisfy everyone.
Topics: Data Interpretation, Statistical; Dose-Response Relationship, Drug; Endpoint Determination; Humans; Indans; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Reply to Drs. Olanow and Rascol.
Topics: Biomarkers; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Indans; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Placebo Effect; Reproducibility of Results; Research Design | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Discordant effects of rasagiline doses in Parkinson disease.
Topics: Dose-Response Relationship, Drug; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2010 |
What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?
Topics: Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design | 2010 |
Delayed start, rapid solution?
Topics: Alzheimer Disease; Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design | 2010 |
Slowing the decline.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Humans; Indans; Parkinson Disease; Selegiline; Ubiquinone | 2010 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2010 |
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2010 |
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cost-Benefit Analysis; Dopamine Agonists; Humans; Indans; Markov Chains; Models, Economic; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; United Kingdom | 2011 |
MAO inhibitors.
Topics: Depression; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2011 |
Rasagiline-induced serotonin syndrome.
Topics: Aged; Female; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Serotonin Syndrome | 2011 |
[Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].
Topics: Aged; Female; Humans; Indans; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2010 |
[Disease-modifying therapies in PD].
Topics: Animals; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Endpoint Determination; Humans; Indans; Parkinson Disease; Randomized Controlled Trials as Topic | 2010 |
[The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].
Topics: Aged; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Speech Disorders; Treatment Outcome | 2011 |
Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.
Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2011 |
Development of Parkinson's disease in patients with Narcolepsy.
Topics: Adult; Age of Onset; Antiparkinson Agents; Cataplexy; Central Nervous System Stimulants; Deep Brain Stimulation; Dextroamphetamine; Female; Humans; Hypokinesia; Indans; International Classification of Diseases; Levodopa; Male; Middle Aged; Narcolepsy; Neuroprotective Agents; Parkinson Disease; Sleep; Young Adult | 2012 |
Livedo reticularis associated with rasagiline (azilect).
Topics: Aged; Female; Humans; Indans; Leg; Livedo Reticularis; Parkinson Disease | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Rasagiline: a guide to its use in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease.
Topics: Animals; Apoptosis; Behavior, Animal; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Humans; Indans; Lactic Acid; Male; Microspheres; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Rotenone | 2012 |
[Medical therapy for Parkinson's disease--the current state of the art].
Topics: Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2012 |
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.
Topics: Aged; Amphetamine; Antiparkinson Agents; Drug Substitution; Female; Humans; Indans; Male; Methamphetamine; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Selegiline; Severity of Illness Index; Time Factors | 2013 |
Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases.
Topics: Aged; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2013 |
Monoamine oxidase inhibitors--is it time to up the TEMPO?
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome | 2003 |
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Carbamates; Cell Line; Enzyme Activation; Enzyme Inhibitors; Humans; Indans; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Parkinson Disease; Rats; Signal Transduction | 2003 |
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Topics: Animals; Apoptosis; Enzyme Inhibitors; Humans; Indans; Models, Chemical; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neurotoxins; Pargyline; Parkinson Disease; Propylamines; Time Factors | 2004 |
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Topics: Animals; Brain; Drug Delivery Systems; In Vitro Techniques; Indans; Iron Chelating Agents; Male; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotective Agents; Pargyline; Parkinson Disease; Piperazines; Propylamines; Quinolines; Rats; Rats, Sprague-Dawley | 2004 |
[Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
Topics: Animals; Antiparkinson Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2005 |
Reexamination of the TEMPO Study.
Topics: Antioxidants; Antiparkinson Agents; Artifacts; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Selegiline; Treatment Outcome | 2005 |
Rasagiline.
Topics: Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Industry; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 2005 |
[Rasagiline in motor fluctuations].
Topics: Drug Therapy, Combination; Humans; Indans; Monoamine Oxidase Inhibitors; Movement; Neuroprotective Agents; Parkinson Disease | 2005 |
Rasagiline -- is there a place for this drug in managing Parkinson's disease?
Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2006 |
[The early therapy challenge].
Topics: Antiparkinson Agents; Dopamine; Humans; Indans; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic | 2005 |
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Topics: Antiparkinson Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Drug Utilization; Finland; Humans; Indans; Levodopa; Markov Chains; Models, Statistical; Parkinson Disease; Treatment Outcome | 2006 |
Safety of rasagiline in elderly patients with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Confusion; Disorders of Excessive Somnolence; Dopamine Agonists; Double-Blind Method; Female; Hallucinations; Humans; Hypotension, Orthostatic; Incidence; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic | 2006 |
Clinical trials with rasagiline: evidence for short-term and long-term effects.
Topics: Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Pargyline; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Selegiline; Treatment Outcome | 2006 |
Rasagiline as a therapy for Parkinson's disease (PD).
Topics: Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline | 2007 |
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.
Topics: Alkynes; Cell Death; Cell Line, Tumor; Energy Metabolism; Genetic Markers; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Membrane Potentials; Mitochondria; Neuroblastoma; Neuroprotective Agents; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pargyline; Parkinson Disease; Propylamines; Proto-Oncogene Proteins c-bcl-2; Selegiline | 2007 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 1995 |
Neuroprotection by (-)-deprenyl and related compounds.
Topics: Aging; Amphetamines; Animals; Antioxidants; Apoptosis; Cattle; DNA Damage; DNA, Neoplasm; Indans; Monoamine Oxidase Inhibitors; Neuroblastoma; Neuroprotective Agents; Nitrates; Oxidants; Parkinson Disease; Selegiline; Tumor Cells, Cultured | 1999 |
The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
Topics: Animals; Cell Survival; Cells, Cultured; Female; Fetus; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 2000 |
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Cell Line; Cell Nucleus; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Immunoblotting; Immunohistochemistry; Indans; Membrane Potentials; Mitochondria; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Salsoline Alkaloids; Signal Transduction; Tetrahydroisoquinolines; Transfection | 2001 |
Rasagiline. Teva Pharmaceutical.
Topics: Administration, Oral; Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship | 2002 |
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Topics: Aged; Amines; Brain; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Indans; Kynuramine; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline; Serotonin; Tissue Distribution; Tranylcypromine | 1986 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine | 1987 |